Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Berzosertib by Merck for Solid Tumor: Likelihood of Approval
Berzosertib is under clinical development by Merck and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Data Insights
Berzosertib by Merck for Neuroendocrine Cancer: Likelihood of Approval
Berzosertib is under clinical development by Merck and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase II...